New Capital Healthcare Disruptors Fund USD N Acc

Reference Data

ISIN IE00BKY80M12
Valor Number 110726988
Bloomberg Global ID
Fund Name New Capital Healthcare Disruptors Fund USD N Acc
Fund Provider EFG - New Capital EFG Asset Management (UK) Ltd
Park House, 116 Park Street
London, W1K 6AP, United Kingdom
Phone: +44 207 173 8011
E-Mail: enquiries@newcapital.com
Fund Provider EFG - New Capital
Representative in Switzerland CACEIS (Switzerland) SA
Nyon
Phone: +41 22 360 94 00
Distributor(s) EFG Bank AG
Zürich
Asset Class Bonds
EFC Category
Distribution Policy Accumulation
Home Country Ireland
Issuing Condition The fund does not charge any issuing commission and/or fees (units are issued at the NAV)
Redemption Condition The fund does not charge any redemption commission and/or fees (units are redeemed at the NAV)
Investment Strategy *** The investment objective of the Sub-Fund is to achieve capital appreciation through investment in a portfolio of equity securities. In order to achieve its investment objective, the Sub-Fund will invest in equities issued by US companies listed or traded on Recognised Markets in the United States such as the NASDAQ, the New York Stock Exchange, the American Stock Exchange, the Chicago Mercantile Exchange and the Chicago Board of Trade across all market capitalizations. The Sub-Fund may invest up to a maximum of 20% of the Net Asset Value in non-US companies including up to 10% of its assets in securities of emerging market issuers.
Peculiarities

Fund Prices

Current Price * 93.89 USD 12.11.2024
Previous Price * 95.35 USD 11.11.2024
52 Week High * 96.27 USD 19.09.2024
52 Week Low * 77.24 USD 14.11.2023
NAV * 93.89 USD 12.11.2024
Issue Price *
Redemption Price *
Closing Price *
Indicative Minimum Price
Fund Assets *** 82,109,755
Unit/Share Assets *** 1,268,494
Trading Information SIX

Performance

YTD Performance +8.85% 29.12.2023
12.11.2024
YTD Performance (in CHF) +14.07% 29.12.2023
12.11.2024
1 month +0.57% 14.10.2024
12.11.2024
3 months +4.08% 12.08.2024
12.11.2024
6 months +8.47% 13.05.2024
12.11.2024
1 year +26.90% 13.11.2023
12.11.2024
2 years +20.88% 14.11.2022
12.11.2024
3 years -16.65% 12.11.2021
12.11.2024
5 years -6.11% 18.05.2021
12.11.2024

Tax Data

Equity Participation Rate in %
Share of Total Fund Assets in %
Real Estate Rate in %
ADDI
ADDI Date

Top 10 Holdings ***

argenx SE ADR 5.68%
Intuitive Surgical Inc 5.22%
Natera Inc 5.11%
Veracyte Inc 4.78%
Veeva Systems Inc Class A 4.28%
Ultragenyx Pharmaceutical Inc 4.24%
Exact Sciences Corp 4.22%
Zoetis Inc Class A 3.97%
Stryker Corp 3.94%
IQVIA Holdings Inc 3.72%
Last data update 31.10.2024

Cost / Risk

TER 3.2965%
TER date 30.06.2021
Performance Fee ***
PTR
Max. Management Fee *** 1.70%
Ongoing Charges *** 3.00%
SRRI ***
SRRI date *** 31.10.2024

ESG Fund Ratings

Low Carbon Designation ***
ESG Rating Overall ***
ESG Rating Corporate ***
ESG Rating Sovereign ***
% AuM H&S Controversies ***

Breakdowns

Countries ***

Stock Sectors ***

Bond Sectors ***

ESG Carbon Metrics

Avg Carbon Risk Score ***
Avg Carbon Risk Cat Avg ***
% AuM Covered Carbon ***
Avg Fossil Fuel Exposure ***
Fossil Fuel Cat Avg ***

ESG Strategy

Strategy Level 1 ***
Strategy Level 2 ***
Strategy Level 3 ***
Exclusions Level 1 ***
Exclusions Level 2 ***

* NAV / Issue Price exclusive commissions, for listed funds NAV or closing price
** Calculation of interim profit followed § 9 Satz 2 InvStG
*** Data source: Morningstar (Data is based on the rescaled long position of the holdings)